BlackRock’s Grace Therapeutics GRCE Stock Holding History

BlackRock’s Portfolio GRCE Stock Details GRCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-10	Closed	-$31	–	5745
2022 Q4	$31	Buy	+10	New	+$29	﹤0.01%	5746

Other funds holding GRCE

TPCW

TD Private Client Wealth New York $4.82B AUM 15.21% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ASN

Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return

BlackRock's GRCE Position: Q1 2023 in Review

BlackRock sold out of Grace Therapeutics (GRCE) in Q1 2023, closing a stake of 10 shares — an estimated $31 sold.

BlackRock first reported a position in GRCE in Q4 2022 and held it in 1 quarter. The position peaked at $31 in Q4 2022. 13 funds tracked by Wall St. Rank hold GRCE as of Q1 2023.

BlackRock reported no remaining Grace Therapeutics position as of Q1 2023 after selling out during the quarter.
BlackRock sold 10 Grace Therapeutics shares in Q1 2023, an estimated $31.
BlackRock first reported a position in Grace Therapeutics in Q4 2022 and held it in 1 quarter.
BlackRock's Grace Therapeutics position peaked at $31 in Q4 2022.
13 funds tracked by Wall St. Rank held Grace Therapeutics as of Q1 2023.

Based on BlackRock's 13F filing for Q1 2023, filed 12 May 2023.